Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions
Molecular Pharmaceutics · 06.10.2025 · 22 (10) · 6151-6162
DOI: 10.1021/acs.molpharmaceut.5c00856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 15.09.2025. Verfasst von Xin Ding und 5 weiteren Autor:innen. Beteiligte Einrichtung: Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475000, China. Hauptthemen laut MEDLINE: Macrophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Henan Medical Science and Technique Foundation, National Natural Science Foundation of China, Key Science and Technology Program of Kaifeng City in Henan Province.
Abstract (Originalsprache)
Chimeric antigen receptor macrophages (CAR-Ms), which are genetically engineered, have application prospects in solid tumor therapy because of the prominent role of macrophages in the tumor microenvironment. Recently, non-natural sugar metabolic labeling based on bioorthogonal reactions has emerged as a research hotspot in targeted tumor therapy. In this study, 4T1 cells and M1 macrophages were incubated with Ac4GalBCN and Ac4ManNAz, respectively, to equip the cell surfaces with -BCN and -N3 groups. These modifications enhanced the proximity between these two kinds of cells and promoted phagocytosis and cytokine release. Moreover, compared to other groups, the bioorthogonal labeling group exhibited heightened tumor-targeted effects and antitumor phagocytic activity against 4T1 cells in vivo. Addition of the small-molecule inhibitor RRx-001 further improved the synergistic effect on phagocytosis and immune cell phenotypes in tumors. In summary, our study highlights the metabolic labeling strategy as a potent approach to promote M1 macrophage-mediated antitumor responses within the tumor environment, providing a novel means for the development of therapeutic strategies tailored for solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475000, China.
- College of Pharmacy, Henan University, Kaifeng 475000, China.
ORCID-Profile: Jiajia Wang
Förderung
- Henan Medical Science and Technique Foundation
- National Natural Science Foundation of China
- Key Science and Technology Program of Kaifeng City in Henan Province
- Henan Province colleges and universities young backbone teacher training program
Zitieren
APA
Ding, X., Zhang, Y., Chu, S., Huang, S., Wang, J., & Li, X. (2025). Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions. Molecular Pharmaceutics, 22(10), 6151-6162. https://doi.org/10.1021/acs.molpharmaceut.5c00856
Vancouver
Ding X, Zhang Y, Chu S, Huang S, Wang J, Li X. Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions. Molecular Pharmaceutics. 2025;22(10):6151-6162. doi:10.1021/acs.molpharmaceut.5c00856
BibTeX
@article{Ding2025,
author = {Ding, Xin and Zhang, Yang and Chu, Songshen and Huang, Song and Wang, Jiajia and Li, Xia},
title = {Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {10},
pages = {6151--6162},
doi = {10.1021/acs.molpharmaceut.5c00856}
}
EUVIMED